Where do Corvus Pharmaceuticals's ratios come from?

Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Returns
Return on equity	-30.5%+2.1pp	-32.6%+3.2pp	-35.8%+32.9pp	-68.7%+31.5pp	-100.1%+74.7pp
Return on assets	-28.3%-6.4pp	-21.8%-0.2pp	-21.6%+37.0pp	-58.6%+24.6pp	-83.2%+25.7pp
Return on invested capital	-38.8%+65.3pp	-104.2%-4.5pp	-99.6%-31.1pp	-68.5%+17.7pp	-86.2%+19.0pp
Liquidity
Current ratio	19.8×+13.6×	6.2×-2.1×	8.3×-0.6×	8.9×+4.0×	4.9×+3.4×
Quick ratio	19.8×+13.6×	6.2×-2.1×	8.3×-0.6×	8.9×+4.0×	4.9×+3.4×
Cash ratio	3.3×+2.8×	0.5×+0.1×	0.4×-1.4×	1.7×+1.2×	0.5×+0.3×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$2.67+248%	$0.77-11.4%	$0.87-16.0%	$1.03+57.2%	$0.66+22.9%
Valuation
Market capitalization	$1.1B+259%	$575.05M+4.7%	$549.17M+64.1%	$334.68M+54.5%	$216.67M-37.0%
Enterprise value	$1.06B+251%	$571.41M+4.4%	$547.31M+70.5%	$321.07M+50.9%	$212.83M-36.7%
Price / book	4.6×-1.6×	9.4×+1.7×	7.7×+3.5×	4.2×-0.2×	4.4×-6.2×
Earnings yield	-4%+9.5pp	-2.7%+0.1pp	-2.7%+10.7pp	-13.5%+5.6pp	-19.1%-1.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Corvus Pharmaceuticals's ratios come from?: Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.